Phaseline

Companies › iQure Australia

iQure Australia: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Neurology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
iQ-007
Positive allosteric modulator of excitatory amino acid transporter-2 (EAAT2)
SLC1A2Phase 1Drug Resistant Epilepsy–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06899230iQ-007Phase 1Drug Resistant EpilepsyNeurologyJan 2026

Targets

SLC1A2 (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.